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Transcription Activation by a PNA-Peptide
Chimera in a Mammalian Cell Extract
mains could perhaps be obtained by screening combi-
natorial libraries for molecules that bind coactivators or
other relevant protein targets.
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Department of Internal Medicine Recently, there have been several advances in this
area. Dervan, Ptashne, and colleagues reported that aDepartment of Molecular Biology and
Department of Pharmacology synthetic molecule comprised of a hairpin polyamide
linked to a peptide was able to activate transcription inUniversity of Texas Southwestern Medical Center
5323 Harry Hines Boulevard vitro in a yeast nuclear extract [15–17]. Stanojevic and
Young found that activating peptides tethered to a triple-Dallas, Texas 75390
helix-forming oligonucleotide could induce transcription
activation [18]. This work is significant in that it repre-
sents the first example of activation of transcription bySummary
a synthetic molecule in cultured cells. These results
demonstrate the feasibility of making synthetic activa-Synthetic activators that mimic the ability of native
tors, though the peptide activation domains in thesetranscription factors to recruit the RNA polymerase
molecules were not derived from simple binding studies,holoenzyme to specific promoters could, in principle,
but instead were taken from known activators or derivedbe constructed by joining a sequence-specific DNA
from functional genetic selections.binding moiety with a molecule able to bind the holoen-
Two studies have demonstrated that peptides se-zyme. We report here that a peptide nucleic acid (PNA)-
lected solely on the basis of their ability to bind a targetpeptide chimera is capable of activating transcription
protein can function as activation domains in cells whenin vitro in a HeLa nuclear extract. Specifically, a pro-
fused to an appropriate DNA binding domain. In the firstmoter-targeted PNA alone acts as a strong inhibitor
such report, we demonstrated that 20 residue peptidesof basal transcription in a HeLa nuclear extract, pre-
selected from a phage-displayed library for binding tosumably due to structural modification of the pro-
the transcriptional repressor Gal80 had activity in yeastmoter. However, the fusion of a Gal80-binding peptide
[19]. Subsequently, Frangioni and colleagues showedto the PNA, but not control peptides, reactivates tran-
that eight residue peptides, again isolated by phagescription. The Gal80-binding peptide was selected
display, that bind the KIX domain of the coactivator Crebsolely on the basis of its ability to bind the yeast re-
binding protein (CBP) have activity in mammalian cells [20].pressor.
Recently, we communicated the synthesis and prelim-
inary characterization of a chimeric molecule comprised
Introduction of a “clamp-type” PNA fused via a flexible linker to one
of the Gal80 binding peptides derived from phage dis-
In eukaryotic cells, the expression of most genes is play [21]. It was shown that this molecule could bind
regulated by gene-specific transactivators. Most of these DNA and recruit either the Gal80 protein or the Gal11
proteins are comprised of sequence-specific DNA bind- protein [22, 23], a yeast coactivator, to the bound DNA,
ing and activation domains (ADs). ADs bind to one or thus reconstituting a fundamental property of activators.
more proteins in various transcription complexes, such In this study, we report the further characterization of
as the RNA polymerase II holoenzyme [1–3] and chroma- this novel molecule. In particular, we show that a Gal4
tin remodeling/modification machines [4]. These two DBD-Gal80 binding peptide is capable of transcriptional
binding properties allow activators to function, at least in activation in mammalian cells, even though the protein
part, by attracting these enzymatic complexes to nearby against which the peptide was selected is from yeast.
promoters, thus stimulating gene expression [5–8]. Syn- We also analyze the activity of the PNA-peptide chimera
thetic molecules that promote gene-specific activation in transcription experiments in vitro using human nuclear
would be powerful tools for biological research and extracts. Interestingly, the PNA alone has a potent re-
could potentially be of medical interest as well. It has pressive effect on the basal level of transcription. It is
been suggested that artificial activators which reconsti- shown that fusion of the Gal80 binding peptide reacti-
tute the recruitment activity of native transcription fac- vates robust transcription whereas control peptides do
tors could be made by linking together appropriate syn- not. A number of other controls and DNA binding experi-
thetic DNA- and protein binding moieties [9]. To execute ments are presented which, together, argue that this
such a plan of course, one must have in hand the appro- synthetic molecule indeed has transactivation activity.
priate specific DNA- and protein binding molecules. These results represent the first observation of activity
There exist certain classes of molecules capable of bind- of this type using a molecule whose components were
ing DNA sequences specifically, such as the hairpin poly- obtained completely by design and binding-based screen-
amides developed by Dervan and colleagues [10–12] ing experiments. Thus, these experiments, combined with
and the peptide nucleic acids (PNAs) pioneered by Niel- the previous work mentioned above, complete an impor-
sen and coworkers [13, 14]. Synthetic activation do- tant proof of principle for a pathway to the development




Table 1. Transcription Activities of Polypeptides Measured by
Luciferase Assay




Gal4(1-147)-20un-G80BP-A 46  4
Gal4(1-147)-(G80BP-A)2 653  60
Gal4(1-147)-(G80BP-A)3 4680  500
Gal4 3007  500
Gal4(1-147)-VP16 9220  550
The fold activation is defined as the ratio of transcription driven by
the indicated construction and the DNA-binding domain [Gal4(1-147)],
which is normalized to one.
Results
The Gal80 Binding Peptide Functions as an
Activation Domain in Mammalian Cells
In previous work [19], we used phage display to identify
two peptides that bind tightly and specifically to the
Gal80 protein. Gal80 is a transcriptional repressor that
blocks activation of the Gal4 transactivator by binding
tightly to the activation domain of that protein [24]. The
Figure 1. Schematic View of the DNA Templates Used in This Studyhope was that a Gal80 binding peptide would serve as
(A) Firefly luciferase-encoding reporter gene for mammalian cella mimic of the potent Gal4 AD. Both peptides, when
culture experiments with five consensus Gal4 binding sites in the
expressed as a fusion with the Gal4 DNA binding domain promoter-proximal region.
(DBD), indeed supported transcriptional activation in (B) G-less cassette reporters for in vitro transcription experiments
yeast [19]. As a first step toward the development of a containing zero, one, or five BisPNA binding sites in the promoter-
proximal region. The distance between the PNA binding sites andsynthetic activator that would function in mammalian
the TATA box is indicated for DNAs 2 and 3.cells, we asked if one of these peptides, Gal80 binding
peptide A (G80BP-A) (Table 1) [19], would activate tran-
scription in cultured mammalian cells, even though it
activation. Activators with two or three copies ofwas isolated against a yeast transcription factor.
G80BP-A drove 650- and 4700-fold higher levels, re-A number of constructs that encode Gal4(1-147)-pep-
spectively, of luc expression than did the DBD alone.tide(s) fusion proteins were constructed by subcloning
The peptide with three consecutive G80BP-A units hasthe protein-encoding fragments employed for our previ-
transcription activity close to that of Gal4 and VP16ous yeast studies into the mammalian expression vector
activation domain. We conclude that G80BP-A functionspEGFP-N3 (Promega). These expression plasmids were
as a weak activation motif in mammalian cells, but thatcotransfected into 293 cells along with a reporter plas-
potent activation can be achieved through multimeri-mid, pG5B, which has five Gal4 binding sites upstream
zation.of the promoter driving the firefly luciferase (Luc) gene
(Figure 1A). A Renilla luciferase expressing vector with
the SV40 enhancer, pRL-SV40, was also added to the Characterization of PNA-Peptide Chimeras
As reported previously [21], we have synthesized andtransfection mixture to provide an internal control for
transfection efficiency. purified a PNA-G80BP-A chimera and demonstrated
that it is capable of recruiting transcription proteins toThe normalized Luc activities driven by each Gal4-
peptide(s) construct are shown in Table 1, with the level the DNA to which it is bound. Here we examine the
transcription activation activity of this molecule in aobserved in the presence of Gal4(1-147) set to one. The
Gal4(1-147)-G80BP-A fusion gave a 6-fold increase of mammalian nuclear extract.
To facilitate these experiments, a number of PNA-the transcription level, whereas fusion of a control pep-
tide, 20un (a 20-mer picked randomly from the library) peptide conjugates (Figure 2) were created and their
DNA binding properties characterized. BisPNA was de-provided a 2-fold increase. For comparison, fusion of the
native Gal4 or VP16 activation domains to Gal4(1-147) signed to bind the double-stranded DNA sequence
5-AAGGAGGAGA-3, a favorable site for PNA complex-provided much higher levels of activation (about 3000-
and 9200-fold, respectively). However, when the 20un ation. MisPNA has four mismatched bases relative to
BisPNA and is therefore not expected to associatepeptide was inserted between the Gal4 DBD and
G80BP-A, a more robust 46-fold increase in Luc expres- tightly with this DNA sequence. PNAs were synthesized
using automatic solid-phase synthesis. G80BP-A andsion was observed, suggesting that a spacer between
the two functional motifs is required for full activity. 20un peptides were added to the PNAs by manual solid-
phase synthesis.Finally, as we had observed in yeast cells [19], multimeri-
zation of G80BP-A resulted in a synergistic increase in To assess the DNA binding properties of the PNA-
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Figure 2. Structures of the Synthetic Activators
(A) Schematic view of the BisPNA-peptide·DNA complex illustrating
the strand invasion mode of binding.
(B) Chemical structures of the components employed to make the
PNA-peptide chimeras.
peptide conjugates, 32P-labeled double-stranded DNAs Figure 3. Footprinting Analysis of PNA·5-32P-Labeled DNA Com-
plexesof about 500 base pairs were produced by PCR. These
Complexes were preformed as described in the text and ExperimentalDNAs contained either one or five binding sites for the
Procedures section, and these complexes were probed with DNaseI.BisPNA-peptide molecules, as well as a core promoter
(A) DNA template containing five PNA binding sites (DNA1, Figureand a 377 bp G-less cassette (Figure 1B). A 200-fold
1B). Lane 1, undigested DNA. Samples in lanes 2–6 were all digestedmolar excess of PNA-peptide was incubated with the with DNaseI. Lane 2, DNA alone; lane 3, DNA  MisPNA-G80BP-A;
DNA for 16 hr at room temperature. The large excess of lane 4, DNA  BisPNA-G80BP-A; lane 5, DNA  BisPNA-20un; lane
PNA-peptide conjugate was necessary because strand 6, DNA  BisPNA (no peptide fusion).
(B) DNA template with one PNA binding site (DNA2, Figure 1B). Laneinvasion (Figure 2A) of PNA-peptides into linear DNAs
1, undigested DNA. Samples in lanes 2–4 were digested with DNaseI.is a slow process at neutral pH [25, 26]. After binding,
Lane 2, DNA alone; lane 3, DNA  BisPNA-G80BP-A; lane 4, DNA the excess PNA-peptide molecules were removed by a
BisPNA (no peptide fusion). In both gels, the major site of PNAPCR-like purification protocol [21]. binding is indicated and corresponds to the expected protection of
The purified PNA-peptide·DNA complexes were sub- the target site(s). A lighter footprint (striped bar) was also observed
jected to DNase I footprinting to examine their binding for the BisPNA constructs, indicating a weaker association with a
region of the G-less cassette.chemistry. In Figure 3A, the DNA template containing
Chemistry & Biology
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five BisPNA binding sites (DNA1; Figure 1B) was em-
ployed. As anticipated, the BisPNA molecule lacking a
fused peptide provided a strong footprint (compare
lanes 2 and 6) at the expected site (as determined by
sequencing; data not shown), whereas the control mole-
cule, MisPNA, did not provide such a footprint (compare
lanes 2 and 3). Lanes 4 and 5 show that the BisPNA
molecules with either the G80BP-A or 20un peptides
fused to them exhibit a footprint nearly identical to that
of the parent BisPNA (compare with lane 6). The only
significant difference is a single site of nuclease hyper-
sensitivity in the BisPNA-20un·DNA complex, which we
cannot explain. These data prove that the PNA mole-
cules exhibit the anticipated sequence specificity and
that fusion of the activating or control peptides does
not compromise DNA binding.
In Figure 3B the DNA template contained one PNA
binding site (DNA2; Figure 1B). The BisPNA·DNA and
BisPNA-G80BP-A·DNA had similar footprints (compare
lanes 3 and 4 with lane 2). The indicated binding region
was determined by DNA sequencing (data not shown).
These results prove that BisPNA and BisPNA-peptide
can bind to a single site on DNA.
The footprinting experiments also provided some evi-
dence for lower affinity binding of the BisPNA-con-
taining molecules to the G-less cassette region (striped
bar in Figure 3). This was not completely unexpected
since there were sites in the cassette very similar to the
Figure 4. Results of In Vitro Transcription Reactions Carried Out in
designed target site (5-AAGGAGGAGA). HeLa Nuclear Cell Extracts
The identities of the DNA and synthetic construct (if present) are
indicated.
In Vitro Transcription
For in vitro transcription experiments, reporter plasmids
containing either zero, one, or five PNA binding sites, a To confirm that the transcription activation was caused
by G80BP-A tethered to the DNA via the PNA moiety,core promoter, and a G-less cassette were linearized
with HindIII. These linear DNAs of about 3000 bps were similar experiments were conducted with various other
PNA-containing constructs. As shown in lane 5 of Figureincubated with a 170-fold molar fold excess of PNA or
PNA-peptide chimera for 16 hr at room temperature. 4A, the BisPNA-20un chimera repressed transcription.
This important control demonstrates that the fusion ofThe PNA-peptide·DNA complexes were purified by PCR
purification protocol as discussed above for the foot- a control peptide to the PNA does not derepress tran-
scription and that the special activating characteristicsprinting experiments. The preformed complexes were then
added to HeLa nuclear extract and transcription was of G80BP-A are required to obtain strong RNA synthesis.
Second, the level of transcription observed when themeasured [27].
Figure 4A shows the results of experiments conducted DNA template had been incubated with MisPNA or Mis-
PNA-G80BP-A was identical within error to that ob-with DNA1 (Figure 1B), the template that contains five
binding sites for the BisPNA molecule upstream of the served in the basal reaction (compare lanes 6 and 7,
respectively, to lane 4 in Figure 4A), as expected fromcore promoter.
The distance between PNA binding sites and the TATA the fact that MisPNA does not bind the sites in this
template (see Figure 3).box is 27 base pairs. Lanes 1 and 4 in Figure 4A reflect
the level of basal (unactivated) transcription observed To further probe the correlation between PNA-DNA
binding and repression of transcription, transcriptionin this system, as no PNA construct was bound to the
DNA in these experiments. As shown in lane 2, binding experiments were conducted with the DNA3 template
(Figure 1B) that lacks PNA binding sites. In this case,of BisPNA lacking an appended peptide strongly re-
pressed transcription, possibly due to PNA-mediated the addition of BisPNA or the BisPNA-G80BP-A chimera
had no effect on transcription, the levels observed beinginterference of the assembly of the transcription com-
plex and/or perturbations in the DNA structure due to identical to those seen in the basal reaction (Figure 4B,
compare lanes 2 and 3 with lane 1). Thus, we concludePNA invasion. When the BisPNA-G80BP-A hybrid was
bound to the DNA template, much more robust tran- that sequence-specific recognition of the DNA template
by the PNA moiety is essential for both PNA-mediatedscription was observed. The level was slightly higher
than that observed in reactions lacking a PNA (lane 1). repression of transcription as well as G80BP-A-depen-
dent reactivation of transcription. Figure 4C shows theThis result shows that the presence of the Gal80 binding
peptide can rescue a repressed template and reactivate results of experiments using a template containing a
single BisPNA binding site, DNA2. In this case, BisPNAtranscription.
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also repressed basal transcription (lane 2 compared with provided a much “cleaner” background against which
to evaluate the activity of G80BP-A.lane 1), but much less severely than was the case for
the multiple PNA binding site template. The transcription As shown in Figure 4, the level of transcription in vitro
supported by BisPNA-G80BP-A was at least 10-foldlevel observed when the BisPNA-G80BP-A molecule
was bound to the template was similar to that seen in greater than that which was obtained from the BisPNA-
bound template (compare lanes 2 and 3 in Figure 4A).the basal experiment.
However, fusion of a control peptide, 20un, to the PNA
did not stimulate transcription (lane 5), showing the spe-
Discussion cific effect of the Gal80 binding peptide. The level of
transcription supported by the BisPNA-G80BP-A conju-
In this paper, we have demonstrated that G80BP-A, a gate was consistently higher than that of the basal reac-
20-mer peptide selected against Gal80 in yeast, is able tion, but only modestly so. Therefore we were initially
to act as a transcription activation domain in mammalian concerned that the apparent reactivation of repressed
cells. As was the case in yeast cells [19], a single copy of transcription mediated by BisPNA-G80BP-A might be
G80BP-A fused to the Gal4 DBD supports only modest due to poor DNA binding of this construct and that
levels of activation, but multimerization of the peptide the activity observed was essentially the basal reaction.
resulted in a synergistic increase in activation. Three However, this model was refuted completely by the
copies of the peptide supported a level of activation DNaseI footprinting experiments shown in Figure 3. The
similar to that of the potent Gal4 and VP16 native activa- binding characteristics of the BisPNA lacking a peptide,
tion domains. We note that there is good evidence that BisPNA-G80BP-A, and BisPNA-20un were almost iden-
native ADs themselves are probably comprised of syner- tical. Fusion of the peptide to the PNA did not compro-
gistically interacting peptide units [28, 29], so we sus- mise DNA binding activity in any way. We note that the
pect that the Gal80 binding peptide is a mimic of just conditions under which the PNA·DNA complexes were
such a functional native unit. These results spurred us formed in the footprinting and transcription assays were
to examine the activity of the Gal80 binding peptide in identical. Thus, we conclude that the BisPNA-G80BP-A
vitro in mammalian nuclear extracts in the context of a indeed functions as an activator in the mammalian nu-
completely synthetic molecule. clear extract.
The results of these experiments, shown in Figure 4, As mentioned in the Introduction, several papers have
were striking. First, binding of the PNA molecule(s) to the now made clear the feasibility of making synthetic tran-
promoter region of the transcription template severely scription factors [15–18]. These molecules consisted of
repressed the relatively high level of basal transcription hairpin polyamide or triplex-forming oligonucleotide
observed in these experiments. The strand invasion of DNA binding elements fused to activating peptides de-
BisPNA forms a P loop structure that disrupts the local rived from native activators or obtained in functional
DNA double helix (Figure 2) [30, 31]. Therefore, a reason- genetic screens [33, 34]. The results reported here ad-
able model is that the PNA·DNA complex is a less opti- vance the field further by demonstrating that a synthetic
mal substrate for binding the transcription machinery activator can be constructed from components that were
and basal activity is thus repressed. One would imagine either designed (the PNA moiety) or obtained through
that the structural disruption in the promoter region simple screening assays based on binding alone (the
would be more severe when the template contains five, Gal80 binding peptide). This is important, because the
rather than one, binding sites, and this correlates with ultimate goal in this area is to develop synthetic activa-
the much greater repression observed for the DNA1 tors that could be used routinely to manipulate gene
versus the DNA2 template. Again, no effect of any of expression in cultured cells and perhaps in animals.
the PNA constructs was observed on transcription from Thus, it will be desirable in the future to move away
template DNA3, which lacks PNA binding sites. from peptides and oligonucleotides and to employ more
Whatever the detailed mechanism of PNA-mediated “drug-like” molecules in these constructs. Although we
repression, it was advantageous in evaluating the activ- have employed a peptide AD mimic in this study, it was
ity of the activation potential of G80BP-A in this assay. isolated solely on the basis of a physical binding assay
Transcription reactions on naked (i.e., nonchromatin) [19], suggesting that nonpeptidic AD surrogates could
templates typically exhibit relatively high basal activity be obtained by screening appropriate combinatorial li-
since the general transcription machinery need not com- braries against Gal80 [19] or the KIX domain of CBP[20].
pete with histones for the promoter. It is generally ac- Of course, genetic and other functional screens cannot
knowledged that most of the activation effect on chro- easily provide nonpeptidic moieties. Finally, these re-
matin templates is due to derepression, with so-called sults also represent the first report of a synthetic activa-
“true activation” (stimulation beyond the basal level) [32] tor that functions in a mammalian nuclear extract.
providing a much more modest contribution. We were The importance of moving toward synthetic activators
concerned that this would make it difficult to evaluate that lack native peptide elements is perhaps highlighted
the activity of what we anticipated would be an artificial by unpublished work from our laboratory. We have in-
AD of only modest potency. Indeed, in our hands, even vested considerable effort in looking for PNA-G80BP-
the potent VP16 AD, when fused to the Gal4 DBD, sup- A-mediated activation in cultured mammalian cells by
ports only a 3- to 5-fold increase in transcription from preforming reporter plasmid (both circular and lin-
naked templates in transcription under these conditions ear)·PNA-G80BP-A complexes in vitro and transforming
(A.F. and T.K., unpublished data). However, the very these species into cells. In no case was significant acti-
vation of the reporter gene observed (B.L. and T.K.,low level of transcription from the PNA-bound template
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NotI-cleaved pEGFP-N3 (Promega) vector. The resultant plasmidsunpublished data). Of course, it is difficult to interpret
were named pEDBD-Peptide(s).negative results of this type, but one possible reason for
The Gal4(1-147)-VP16 fusion oligonucleotide for mammalian cellthe lack of activity is the destruction of the unstructured
expression was made by PCR using pGEX-GSTCS-GAL4(1-147)-
peptide in cells. The PNA-DNA complex is so stable that VP16(78aa) vector as the template. The PCR product was purified
if the peptide were degraded, there would be no chance by QIAGEN gel extraction kit, digested with PstI/NotI, and inserted
into PstI/NotI-cleaved pEGFP-N3 vector. The resultant plasmid wasof exchanging the now inactive species for another mol-
named pEDBD-VP16.ecule of an artificial activator. We note that this model
The firefly luciferase reporter vector pG5B that contains five Gal4is not necessarily in conflict with the reported activity
binding sites in the proximal region of a TATA box was a kind giftof the oligonucleitde-peptide conjugate of Stanojevic
from Dr. Marc R. Montminy (Salk Institute).
and Young [18] in cultured cells. The peptides employed The original G-less cassette reporter plasmids pTF-C2AT for in
in that study lack a lysine residue, which is required for vitro transcription were kindly provided by Dr. Stephen A. Johnston
(UT Southwestern). The reporter plasmids with a single PNA bindingdegradation via the ubiquitin-proteasome pathway [35]
site (pTF-C2AT-P1) and five PNA binding sites (pTF-C2AT-P5) closethat operates on native activators [36], the kinetic half-
to TATA box were constructed by annealing synthetic oligonucleo-life of the synthetic activator·DNA complex is unknown,
tides and inserting the fragment into the EcoR1/BamH1-cleavedand there was excess activator in the cells, whereas we
pTF-C2AT. The plasmid pTF-C2AT-NS containing no PNA bindingtransfected stoichiometric activator·DNA complexes. site was made by cleaving pTF-C2AT with EcoR1 and BamH1, filling
Efforts to isolate nonpeptidic ligands for Gal80 and KIX with Klenow fragment, and religating.
domain are underway in our laboratory.
Strain
Human embryonic kidney 293 cells (American Type Culture Collec-Significance
tion, CRL-1573).
We demonstrate here that it is possible to construct
Cell Culture, Transfection, and Luciferase Assaya synthetic activator that functions in a mammalian
293 cells were grown in 6-well plates at 37C in Dulbecco’s modifiednuclear extract from components that were either de-
Eagle’s medium supplemented with 10% (v/v) fetal calf serum, 400signed or isolated in simple binding assays. These re-
g/ml ampicillin, and 100 g/ml streptomycin. Cells were passed
sults are important because, together with earlier ef- every 24 hr and reached 70% confluence before transfection. The
forts from other laboratories, they complete the proof cells were transfected by the Lipofectamine Plus method (Promega
of principle for a pathway for the generation of syn- protocol) with 1.52 g of total DNA, including 750 ng of pG5B re-
porter vector, 750 ng of the respective pEDBD-peptide(s) vector,thetic activators lacking any native peptide segments.
and 20 ng of Renilla luciferase plasmid (pRL-SV40, Promega) for
normalization. All transfected cultures were maintained at 37C un-Experimental Procedures
der 5% CO2. Luciferase assays were conducted 40 hr after transfec-
tion with a dual-luciferase reporter assay system (Promega). 20%Synthesis
of the total cellular extract was used in each luciferase reaction.Peptide nucleic acids (PNA) monomers Fmoc-T-OH, Fmoc-C(Bhoc)-
OH, Fmoc-G(Bhoc)-OH, Fmoc-A(Bhoc)-OH, and Fmoc-AEEA-OH;
carboxyl activators O-(7-azabenzo-triazol-1-yl)-1,1,3,3-tetrameth- Footprinting
yluronium hexafluorophosphate (HATU) and 1-hydroxy-7-azabenzo- PNA-Peptide·DNA Complexes Preparation
triazole (HoAt) were from Applied Biosystems. Diisopropylethylamine 500 bp DNA sequences containing bisPNA binding sites, a TATA
(DIPEA) and 2,6-lutidine were from Sigma-Aldrich. Fmoc-XAL-PEG- box, and a 377 bp G-less cassette were made by PCR using pTF-
PS resin was from NOVAbiochem. All Fmoc amino acid monomers C2AT-P5 or pTF-C2AT-P1 as the templates. The PCR products were
were from BACHEM and Advanced Chemtech. purified by PCR purification kit (Qiagen). After purification, the DNAs
BisPNA and MisPNA (see Figure 2B for sequences) were synthe- were labeled with [-32P]ATP. 10 g of DNA templates was mixed
sized on an Expedite 8900 Nucleic Acid Synthesis System (Applied with 5 l of [-32P]ATP (6000 Ci/mmol, 10 Ci/l, Amersham), and
Biosystems), using standard fluorenylmethoxy-carbonyl (Fmoc) 1 l (10 unit) T4 polynucleotide kinase (NE Biolabs) in 100 l of
chemistry. Fmoc-XAL-PEG-PS resin was used as solid phase at 2 reaction buffer (NE labs). The reaction mixture was incubated at
mol scale. For each coupling reaction, 10 mol of each monomer, 37C for 60 min. The solution was then extracted with phenol/chloro-
10 mol of HATU, 10 mol of HoAt, 2.5 l of DIPEA, and 1 l of form. The labeled DNA was separated from the unincorporated
2,6-lutidine were used. The reaction was carried in 1 ml of 1-methyl- [-32P]ATP by centrifugation through a Sephadex G-50 column. After
2-pyrrolidinone at ambient temperature for 20 min. When PNA syn- labeling, DNAs were digested with HindIII to remove the 32P labels
thesis was finished, the resins with PNA attached were taken off at the G-less cassette end. The singly 32P end-labeled DNAs were
the synthesizer and placed in a 25 ml frit funnel. G80BP-A and 20un isolated by 0.8% agarose gel electrophoresis and extracted from
peptides (see Figure 2B for sequences) were added to the PNA the agarose gel by a gel extraction kit (Qiagen).
sequences manually by linear solid-phase Fmoc peptide synthesis. 30 nM of the singly 32P end-labeled DNA was mixed with 6 M of
The reaction condition was the same as in the PNA automatic syn- PNA-peptide in 10 mM (pH 7.5) phosphate buffer and 1 mM EDTA
thesis except that each coupling time was 40 min instead of 20 min. at ambient temperature for 16 hr. The PNA-peptide·DNA complexes
The PNA-peptide conjugates were cleaved by trifluoroacetic acid, were purified by Qiagen nucleotide purification kit and stored
purified by reverse-phase HPLC on a C18 column, and lyophilized at20C. The complexes were stable, as no dissociation was found
to dryness. MALDI-TOF: BisPNA, [M1] calculated 6193.2, found within one week.
6188.4; BisPNA-G80BP-A, [MH] calculated 8731.8, found 8729.4; Footprinting Assay
BisPNA-20un [M1] calculated 8138.4, found 8140.3; MisPNA 0.5 g of DNA or 1 g of PNA-peptide·DNA complex was digested
[M1] calculated 6449.1, found 6447.5; MisPNA-G80BP-A [M1] by 1 l of DNase1 (Invitrogen, 1  103 U/l) in 200 l of assay
calculated 8986.8, found 8988.9. buffer (10 mM Tris, 5 mM MgCl2, 1 mM CaCl2, 2 mM DTT, and
100 mM KCl [pH 8.0]) at 37C for 2 min. The reaction solution was
immediately mixed with 700 l of precipitation buffer (648 l ofPlasmids
The Gal(1-147)-peptide(s) fusion oligonucleotides for mammalian ethanol, 2 l of 3 mg/ml yeast tRNA, and 50 l of 7.5 M ammonium
acetate) at70C. The pellets were washed with 70% ethanol twice.cell expression were made by PCR using pGBT9-peptide(s) vectors
[19] as templates. The PCR products were purified using the QIAGEN Samples were electrophoresed on an 8% (5% cross-link) urea-acryl-
amide gel at 1300V for 1.5 hr. Urea was removed by 15% methanolgel extraction kit, digested with PstI/NotI, and inserted into PstI/
Transcription Activation by a PNA-Peptide Chimera
915
and 5% acetic acid before the gel was dried at 80C. The gel was the DNA minor groove by synthetic ligands. Nature 391,
468–471.autographed by exposing to a Kodak X-OMAT film.
PNA binding sites were confirmed by DNA sequencing using a 11. White, S., Baird, E.E., and Dervan, P.B. (1997). On the pairing
rules in the minor groove of DNA by pyrrole-imidazole polyam-standard DNA polymerase protocol (Sequenase 2.0, USB, Amer-
sham Pharmacia). ides. Chem. Biol. 4, 569–578.
12. Gottesfeld, J.M., Neely, L., Trauger, J.W., Baird, E.E., and Der-
van, P.B. (1997). Regulation of gene expression by small mole-In Vitro Transcription
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